Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring stage IV colon cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of metastatic colorectal carcinoma Bidimensionally measurable disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 4,000/mm^3 Granulocyte count at least 1,500/mm^3 Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin greater than 8 g/dL Hepatic: Bilirubin no greater than 1.2 mg/dL AST and ALT less than 2.5 times upper limit of normal (ULN) PT no greater than ULN (not on anticoagulation therapy) Renal: Creatinine no greater than 1.5 mg/dL Creatine clearance greater than 60 mL/min Pulmonary: DLCO at least 60% Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 2 months after study No other concurrent active malignancies Prior malignancies presumed to be cured allowed No other concurrent uncontrolled severe medical problem that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 months since prior adjuvant chemotherapy without disease recurrence No more than 1 prior chemotherapy regimen for metastatic disease Endocrine therapy: Not specified Radiotherapy: Prior adjuvant radiotherapy allowed No prior radiotherapy to more than 25% of total bone marrow Surgery: Not specified Other: No other prior therapy for advanced disease
Sites / Locations
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center